Metys Pharmaceuticals

Metys Pharmaceuticals is a company that provides treatment for chemotherapy-induced peripheral neuropathy, a side effect of several cancer treatments. It develops MP-101, an orally-active modulator of glutamate signalling in spine and brain that can be used in a range of central nervous system disorders, such as depression, cognition, or neuropathic pain.